Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

CoreWeaves quarterly results beat expectations, with raised full-year guidance and a larger AI-compute backlog drawing attention. Bulls say customer prepayments and contract-backed financing address funding concerns, while bears remain focused on heavy debt, interest costs, and capital spending; the stocks reaction has been volatile.

Capricors scheduled Nov. 22 FDA decision on deramiocel for Duchenne muscular dystrophy is dominating discussion, with traders parsing managements upbeat comments and possible label discussions as signs of approval while others warn a CRL remains possible. The earnings update and share-price decline drew attention, but reactions mostly return to the binary regulatory outcome and launch readiness.

Netlists Q3 results and earnings call are driving attention, with traders highlighting improved profitability, Samsung licensing revenue, stronger margins and an upbeat outlook that includes Micron payments. The reaction is broadly bullish, but some investors question the decline in product sales and the lack of concrete SK hynix or Nasdaq updates, while speculation about those catalysts remains unconfirmed.

Rigettis Q3 results missed expectations, with weak revenue and outlook fueling concerns about cash burn, valuation, and how long quantum computing will take to generate meaningful commercial sales. Most traders reacted bearishly, though some argued that technology progress and government support matter more than near-term revenue.

NVDA is under pressure as traders react to scrutiny of CEO Jensen Huang over an alleged relationship with a China-linked executive and concerns about possible export-control and disclosure issues; the allegations remain unproven. The community is split between fears of leadership or regulatory fallout and buyers who see the selloff as overdone given AI-chip demand and upcoming earnings.

LightPaths fiscal first-quarter results are driving attention: revenue missed expectations, while EPS beat, gross margins expanded, and backlog reached a record. Traders are divided between concern that supply-chain delays and the revenue shortfall undermine execution and optimism that backlog growth and improving margins support the longer-term growth story.

Kuras Q3 results and earnings call are drawing attention, with traders highlighting rising KOMZIFTI prescriptions and patient starts alongside an EPS beat. The reaction is broadly upbeat, though discussion also touches on competitive pressure from J&J and a possible stock offering.

AMPXs quarterly results have sparked a sharp selloff despite strong revenue growth and a raised full-year revenue outlook; the slight EPS miss and weaker EBITDA guidance are cited as negatives. Traders disagree over whether the drop is an overreaction to the headline misses, with some buying the dip and others concerned about losses and cash burn.

NextNavs quarterly results drew attention after the company reported an EPS beat and year-over-year revenue growth, but traders questioned whether the earnings update could offset ongoing uncertainty around FCC approval of its proposed spectrum reconfiguration. Views remain split between bulls focused on the spectrums potential strategic value and bears concerned about regulatory delays and the share-price decline.

Costcos announced special cash dividend and renewed share-repurchase program are driving attention, with traders mostly welcoming the large payout and discussing eligibility and whether it could support the shares. Some also speculate about short covering, but that remains unconfirmed.